The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.05
Bid: 2.01
Ask: 2.04
Change: -0.05 (-2.41%)
Spread: 0.03 (1.493%)
Open: 2.05
High: 2.09
Low: 2.00
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

Mon, 20th Dec 2021 11:41

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 27% at 7.72 pence, 12-month range 4.80p-13.85p. The drug discovery and development company completes GBP3.6 million fundraise via placing and subscription of 32.3 million shares at 11.00 pence each. This is an 80% premium to Friday's closing price of 6.10p. Additionally, ImmuPharma secures a GBP2.2 million subscription from investment firm Lanstead.

----------

Proteome Sciences PLC, up 6.1% to 5.20p, 12-month range 3.07p-10.00p. The drug development services provider wins a new contract in excess of GBP1 million from an unnamed "major pharmaceutical company". Under the terms of the contract, Proteome will analyse large cohorts of clinical samples from a phase 3 clinical trial. Work is expected to start early in the first quarter of 2022

----------

AIM - LOSERS

----------

ThinkSmart Ltd, down 21% at 64.22p, 12-month range 51.00p-115.00p. The Australian digital payments platform reaches an agreement with Afterpay to sell its remaining 10% stake in Clearpay in exchange for 1.7 million shares in Afterpay, worth GBP73.4 million. The disposal will be put to a vote of ThinkSmart shareholders at a meeting on January 14, it adds.

----------

Hurricane Energy PLC, down 14% at 3.60p, 12-month range 0.59p-5.30p. The oil and gas company completes a review into events that led to the rejection of its restructuring plan by the High Court of Justice of England & Wales. The review, overseen by Hurricane's non-executive directors and carried out by an independent solicitor, found that the company's prior board "discharged their fiduciary duties diligently and in good faith". The non-executive directors have agreed following the review that no further action is necessary, and that time and resources should now go towards maximising the future revenue and potential of the company.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
22 Dec 2016 08:47

ImmuPharma completes patient recruitment in Lupuzor trial

(ShareCast News) - Specialist drug discovery and development company ImmuPharma confirmed on Thursday that patient recruitment had successfully been completed, on target, within the its pivotal Phase III clinical trial of Lupuzor. The AIM-traded firm described Lupuzor as its lead programme for the p

Read more
16 Nov 2016 10:41

ImmuPharma Says Paper Detailing IPP-204106 Mechanism Published

Read more
14 Sep 2016 16:47

ImmuPharma makes positive progress in Lupuzor trials

(ShareCast News) - Specialist drug discovery and development company ImmuPharma updated the market on the progress of its Phase III clinical trial of Lupuzor - its lead programme for the potential breakthrough compound for Lupus - on Wednesday. The AIM-traded firm said it now had a total of 11 sites

Read more
14 Sep 2016 08:45

ImmuPharma Makes Progress With Lupuzor Phase III Trial

Read more
7 Jun 2016 06:59

ImmuPharma Begins Dosing Of European Patients In Lupuzor Trial

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
4 May 2016 09:17

ImmuPharma 2015 Loss Widens As It Focuses On Lupuzor Development

Read more
27 Apr 2016 15:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
9 Mar 2016 10:27

ImmuPharma Begins Patient Recruitment In Europe For Lupuzor Trial

Read more
15 Feb 2016 15:32

ImmuPharma doses first patients in the US

(ShareCast News) - ImmuPharma's clinical expansion into the US reached a significant point on Monday, with the first dosing of patients in its Phase III trial of the in-development lupus treatment Lupuzor. The AIM-traded drug discovery and development company confirmed in a statement that dosing had

Read more
15 Feb 2016 09:02

ImmuPharma Hopeful As US Patients Begin Dosing In Lupus Clinical Trial

Read more
5 Feb 2016 15:26

ImmuPharma to raise £7.5m for 'blockbuster' drug

(ShareCast News) - The 'blockbuster' potential of a drug in development saw ImmuPharma proposing a £7.5m fund raise on Friday. The AIM-traded specialist drug discovery and development company said the deal included a proposed conditional non-preemptive placing of no less than 11,824,877 Placing Shar

Read more
5 Feb 2016 10:32

WINNERS & LOSERS SUMMARY: Just Eat Leaps As It Gobbles Up Takeaways

Read more
5 Feb 2016 08:34

ImmuPharma Looks To Raise Minimum GBP7.5 Million In Equity (ALLISS)

Read more
7 Dec 2015 09:36

ImmuPharma Says US Sites Open For Lupuzor Phase III Trial Recruitment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.